Sara Al-Zubeidi
Director, Commercial Strategy Consulting Global Pricing and Market Access
Sara Al-Zubeidi is a Director with Clarivate based in London. Sara has 7+ years commercial strategy consulting experience in life sciences, specializing in global pricing and market access.
Sara leads teams for global P&MA engagements on behalf of pharmaceutical and biotechnology companies. Areas of expertise include pricing and access strategy, evidence generation for HTA submission, innovative agreement strategy, HTA landscape analysis, analogue assessments, value proposition/story development and payer objection handling/negotiation tactics. She also has extensive experience in commercial opportunity assessments, including indication and opportunity prioritization and patient flow assessments. Sara has deep expertise across a wide span of therapeutic areas with oncology, orphan/rare diseases, cardiology, renal and metabolic diseases as specialist areas of interest.
Prior to joining consulting, Sara worked in business development specifically for HEOR and Evidence Strategy teams.
Sara has a Master’s degree in Pharmacogenetics and Stratified Medicine at University College of London (UCL) and a BSc (Hons) in Medical Genetics from Queen Mary University of London.
Latest news
Clarivate Presents Cortellis Regulatory AI Assistant to Cut Through Complexity in Safety and Compliance
Powered by agentic AI, new features help regulatory teams improve accuracy and enable faster, more confident decisions across the product lifecycle London, U.K. — December 4, 2025 — Clarivate Plc…
Clarivate and the Chinese Academy of Sciences Release the 2025 Research Fronts Report
Annual report identifies 110 hot and 18 emerging Research Fronts London, U.K. December 3, 2025. Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, and the Chinese Academy…
Clarivate Reveals Global Shifts in Research Collaboration
New report explores multilateral partnerships, Mainland China’s rising influence, and strategic challenges for the U.S. London, U.K. December 2, 2025: Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence,…